Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341391 | 0.84 | HTR2A (0.67) | HTR2AC5AR1 | |
| SCHEMBL4203051 | 0.84 | SIGMAR1 (0.47) | HTR2ASIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL18143022 | 0.78 | HTR2A (0.52) | HTR2AC5AR1MEN1ALDH1A1HTT | |
| SCHEMBL6104472 | 0.75 | SIGMAR1 (0.50) | HTR2ASIGMAR1L3MBTL1 | |
| SCHEMBL6316401 | 0.74 | SIGMAR1 (0.48) | HTR2ASIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL6309994 | 0.73 | OPRK1 (0.48) | HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL6103164 | 0.73 | OPRK1 (0.48) | HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL6104408 | 0.72 | SIGMAR1 (0.47) | SIGMAR1MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL6317318 | 0.72 | SIGMAR1 (0.45) | HTR2ASIGMAR1L3MBTL1 | |
| SCHEMBL341392 | 0.72 | HTR2A (0.62) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885SIGMAR1 295/4885IDO1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.